Ga(III)-DOTATOC

10/01/2023 - "This study aims to propose semi-automated segmentation methods to determine metabolic tumor volume with pretherapeutic 68Ga-DOTATOC PET and evaluate SUVmean-derived values as predictive factors for tumor-absorbed dose. "
01/01/2011 - "Multiple tumor-bearing mice were evaluated with 68Ga-DOTATOC PET studies. "
05/01/2023 - "Our data indicate absent malignancy among incidental 68Ga-DOTATOC findings in the prostate."
12/01/2022 - "68Ga-DOTATOC and 18F-DOPA PET/CT were concordantly positive for tumor multifocality in 5 patients, discordantly positive in 2 patients, and concordantly negative in 1 patient. "
12/01/2022 - "We retrospectively reviewed data from the Cannizzaro Hospital on brain and body 68Ga-DOTATOC PET/CT "incidentalomas", defined as tumors missed on CT or MRI scans, but detected on 68Ga-DOTATOC PET/CT scans. "

01/01/2018 - "Due to the importance of target to non-target ratios in the efficacy of diagnosis, the pharmacokinetic of 68Ga-DOTATOC in an adenocarcinoma breast cancer animal model was studied in this research, and the optimized time for imaging was determined. "
11/01/2021 - "Our case shows that dural metastases from breast cancer might represent a clinical pitfall in 68Ga-DOTATOC PET/CT."
01/01/2018 - "Evaluation of the Possible Utilization of 68Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer."
11/01/2021 - "Breast Cancer Metastasis Mimicking Meningioma in 68Ga-DOTATOC PET/CT."
08/01/2013 - "Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model."

01/01/2022 - "Different adenocarcinomas subtypes present different 18-FDG PET/TC and 68Ga-DOTATOC uptake: An unique case."
01/01/2018 - "Due to the importance of target to non-target ratios in the efficacy of diagnosis, the pharmacokinetic of 68Ga-DOTATOC in an adenocarcinoma breast cancer animal model was studied in this research, and the optimized time for imaging was determined. "
01/01/2018 - "Evaluation of the Possible Utilization of 68Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer."
01/01/2022 - "68Ga-PSMA and 68Ga-DOTATOC PET/CT imaging mismatch of primary pancreatic adenocarcinoma in prostate cancer patient."

08/01/2022 - "68Ga-DOTATOC Embolus Manifestation and Spontaneous Resolution by PET/CT."
08/01/2022 - "Iatrogenic microembolism as a cause of 18F-FDG embolus is well-established; however, 68Ga-DOTATOC embolus is not well documented in the literature. "

06/01/2018 - "Results of this study emphasize the potential of kit-based 68Ga-DOTATOC for PET imaging of neuroendocrine tumors."
01/01/2018 - "Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study."
01/01/2023 - "To evaluate the role of 68Ga-DOTATOC PET parameters in predicting DAXX/ATRX loss of expression in patients with Pancreatic neuroendocrine tumors (PanNET) candidate to surgery. "
12/01/2022 - "Our objective was to compare the respective value of 68Ga-DOTATOC and 18F-DOPA PET/CT for initial staging or presurgical work-up of patients with small-intestine neuroendocrine tumors (SiNETs). "
10/01/2022 - "Methods: Thirty-eight patients with pathologically proven neuroendocrine tumors who underwent 68Ga-DOTATOC PET/CT were studied. "